$Enliven Treateutics(ELVN)$$Terns Pharmaceuticals, Inc.(TERN)$ $Kura Oncology(KURA)$ I’m watching a classic biotech squeeze unfold in Enliven Therapeutics $ELVN. Shares just ripped +44% to fresh 52 week highs after early Phase 1b leukemia data for ELVN-001 surprised to the upside. What matters here is context. Even after today’s vertical move, the stock is only about +2.5% y/y, which tells me this is a sentiment reset, not a late-stage blow off. A long period of dead money met with credible data is exactly how violent re-ratings start. Volume confirms it, momentum traders are pressing, and shorts are scrambling to reprice risk. This is how
Top Calls on Wall Street: Apple, Amazon, Netflix, Nio, Coinbase and More
Here are Friday’s biggest calls on Wall Street:Morgan Stanley reiterates Apple as overweightMorgan Stanley said it’s standing by its overweight rating on shares of Apple.“Apple has underperformed the S&P by 6 pts after a below-expectations Sept Q guide. We remain OW into the iPhone launch as we estimate growth inflects higher in FY24 (driven by iPhone, Services & gross margins), w/ growing LTV [loan to value] a long-term upside driver.”JPMorgan reiterates Netflix as overweightJPMorgan said it’s standing by its overweight rating on Netflix shares.“Our positive view on NFLX hasn’t changed, but the areas of investor pushback we’ve heard most focus on: 1) Paid Sharing monetization & how/when it will lift ARM & revenue; 2) core subscriber growth & NFLX’s future pricing power
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.